IDEXX Laboratories Financials - Benzinga

IDEXX Laboratories Inc

IDXXNASDAQ

Trade with Public

Trade with Public

$532.54

-6.45-1.2%

最終更新: Sep 3, 1:01 PM

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

IDEXX Laboratories Financials

IDEXX Laboratories (IDXX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Why Is IDEXX Laboratories Stock Gaining Tuesday?

IDEXX Laboratories (IDXX) stock rose after reporting Q2 earnings of $4.27/share and $1.22B in revenue, beating Wall Street estimates.

Vandana Singh

PRO
IDEXX Laboratories Raises FY2026 GAAP EPS Guidance from $14.45-$14.90 to $14.69-$14.94 vs $14.67 Est; Narrows FY2026 Sales Guidance from $4.675B-$4.760B to $4.700B-$4.745B vs $4.711B Est

IDEXX Laboratories (NASDAQ:IDXX) raises FY2026 GAAP EPS guidance from $14.45-$14.90 to $14.69-$14.94 vs $14.67 analyst estimate. Narrows FY2026 sales outlook from $4.675 billion-$4.760 billion to $4.700 billion-$4.745

Benzinga Newsdesk

PRO
IDEXX Laboratories Q2 EPS $4.27 Beats $3.96 Estimate, Sales $1.217B Beat $1.201B Estimate

IDEXX Laboratories (NASDAQ:IDXX) reported quarterly earnings of $4.27 per share which beat the analyst consensus estimate of $3.96 by 7.83 percent. This is a 17.63 percent increase over earnings of $3.63 per share from

Benzinga Newsdesk

Idexx Laboratories Raises Guidance On Higher Clinical Visits, Diagnostic Frequency

Idexx Laboratories shares edge higher as revenue tops estimates but earnings per share misses; guidance raised.

Vandana Singh

PRO
CORRECTION: IDEXX Laboratories Q1 EPS $3.47 Beats $3.41 Estimate, Sales $1.141B Beat $1.109B Estimate

IDEXX Laboratories (NASDAQ:IDXX) reported quarterly earnings of $3.47 per share which beat the analyst consensus estimate of $3.41 by 1.76 percent. This is a 20.91 percent increase over earnings of $2.87 per share from

Benzinga Newsdesk

Earnings Scheduled For May 5, 2026

Benzinga Insights

© 2026 Benzinga | All Rights Reserved